目录号 | 产品详情 | 靶点 | |
---|---|---|---|
TN3687 | HBV | ||
Coclauril shows anti-Hepatitis B virus (HBV) activities, with EC50 values of 7.6 ± 0.5 ug/mL. | |||
TN4751 | HBV | ||
Periglaucine B can inhibit hepatitis B virus (HBV) surface antigen (HBsAg) secretion in Hep G2.2.15 cells. | |||
T77063 | |||
Libivirumab (17.1.41) 是一种人源化抗HBV 单克隆抗体。Libivirumab 显示中和活性,对 HBsAg 和 HBeAg 的 IC50值分别为 35、130 ng/mL。 | |||
T40259 | |||
AB-729, a nucleoside analogue functioning as an RNA interference (RNAi), links to a GalNAc (N-acetylgalactosamine) trimer ligand facilitating hepatocyte uptake through the asialoglycoprotein receptor (ASGR). This compound effectively impedes viral replication and diminishes HBV antigens. | |||
T63848 | |||
TLR8 agonist 4 能够有效的抑制野生型和耐药(拉米夫定和恩替卡韦)HBV 菌株,他们的IC50值分别为 0.15 和 0.10 μM。 | |||
T23407 | Others | ||
The nucleocapsid of the hepatitis B virus is covered by an envelope of HBV surface antigen (HBsAg), which has the common, group-specific determinant a. The four major subtypes of HBsAg, adw, adr, ayw and ayr, are generated, and they have been proposed to | |||
T60375 | |||
(-)-5'-Noraristeromycin 是 一种抗病毒剂。(-)-5′-Noraristeromycin 也是 5'-noraristeromycin 的对映异构体,可抑制细胞内 HBV 复制和病毒粒子的产生。(-)-5'-Noraristeromycin 可以用于癌症的研究。 | |||
T70596 | |||
Emtricitabine triphosphate ((-)-Emtricitabine triphosphate) 是恩曲他滨 的磷酸化合成代谢物。Emtricitabine 是一种核苷逆转录酶抑制剂。Emtricitabine 是一种抗逆转录病毒试剂,用于抵抗 HIV 和 HBV 感染。 | |||
T76321 | |||
Brain Derived BasicFibroblast Growth Factor(1-24) (FGF basic 1-24) 是一种合成肽,表现出抗细菌和抗HBV 的活性。Brain Derived BasicFibroblast Growth Factor(1-24) 可用于感染性疾病和免疫性疾病的研究。 | |||
T60374 | |||
L-Fd4A (compound 36) 是腺嘌呤衍生物,具有抗人类免疫缺陷病毒 (HIV) (EC50=1.5 μM) 和抗乙型肝炎病毒 (HBV) (EC50=1.7 μM) 活性。L-Fd4A 具有低细胞毒性。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPK-01492 | HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7).
|
|||||
TMPK-01501 | HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7).
|
|||||
TMPK-01491 | HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 Cells | ||
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7).
|
|||||
TMPY-05822 | Hepatitis B Virus (HBV)(ayw/France/Tiollais/1979) Capsid protein (His) | HBV-D | E. coli | ||
Hepatitis B virus (HBV) capsid assembly is a critical step in the propagation of the virus and is mediated by the core protein. The first cytoplasmic step in the formation of an infectious HBV virion is the formation of a capsid containing pregenomic RNA (pgRNA) and the viral polymerase (Pol). HBV capsid assembly is an attractive target for new antiviral therapies.
|
|||||
TMPH-00803 | HBV-A subtype adw2 (strain Rutter 1979) Capsid protein (His) | HBV-A | E. coli | ||
HBV-A subtype adw2 (strain Rutter 1979) Capsid protein (His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 25.4 kDa and the accession number is P03148.
|
|||||
TMPH-00807 | HBV-D subtype ayw (isolate France/Tiollais/1979) Protein X (His & SUMO) | HBV-D | E. coli | ||
HBV-D subtype ayw (isolate France/Tiollais/1979) Protein X (His & SUMO) is expressed in E. coli expression system with N-6xHis-SUMO tag. The predicted molecular weight is 32.6 kDa and the accession number is P03165.
|
|||||
TMPH-00806 | HBV-D (isolate Germany/1-91/1991) Protein X (His & SUMO) | HBV-D | E. coli | ||
HBV-D (isolate Germany/1-91/1991) Protein X (His & SUMO) is expressed in E. coli expression system with N-6xHis-SUMO tag. The predicted molecular weight is 32.7 kDa and the accession number is O93195.
|
|||||
TMPH-00816 | HBV-A subtype adw2 (strain Rutter 1979) Large envelope protein (His) | HBV-A | E. coli | ||
HBV-A subtype adw2 (strain Rutter 1979) Large envelope protein (His) is expressed in E. coli expression system with N-10xHis tag. The predicted molecular weight is 45.1 kDa and the accession number is P03141.
|
|||||
TMPH-00808 | HBV-D subtype ayw (isolate Japan/JYW796/1988) Protein X (His) | HBV-D | E. coli | ||
HBV-D subtype ayw (isolate Japan/JYW796/1988) Protein X (His) is expressed in E. coli expression system with N-10xHis tag. The predicted molecular weight is 22.6 kDa and the accession number is Q9QMI3.
|
|||||
TMPH-00815 | HBV-A subtype adw2 (isolate Germany/991/1990) Capsid protein (His & Myc) | HBV-A | E. coli | ||
HBV-A subtype adw2 (isolate Germany/991/1990) Capsid protein (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 28.9 kDa and the accession number is P0C693.
|
|||||
TMPH-00804 | HBV-C subtype ayw (isolate China/Tibet127/2002) Capsid protein (Yeast, His) | HBV-C | P. pastoris (Yeast) | ||
HBV-C subtype ayw (isolate China/Tibet127/2002) Capsid protein (Yeast, His) is expressed in yeast with N-6xHis tag. The predicted molecular weight is 23.0 kDa and the accession number is P0C6H7.
|
|||||
TMPH-00805 | HBV-C subtype ayw (isolate China/Tibet127/2002) Capsid protein (E. coli, His) | HBV-C | E. coli | ||
HBV-C subtype ayw (isolate China/Tibet127/2002) Capsid protein (E. coli, His) is expressed in E. coli expression system with N-10xHis tag. The predicted molecular weight is 27.1 kDa and the accession number is P0C6H7.
|
|||||
TMPY-02193 | GOLPH2/GOLM1 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
Golgi membrane protein 1, also known as Golgi membrane protein GP73, Golgi phosphoprotein 2, and GOLM1, is a protein that belongs to the GOLM1 / CASC4 family. GOLM1 is widely expressed. It is highly expressed in the colon, prostate, trachea, and stomach. It is expressed at a lower level in testis, muscle, lymphoid tissues, white blood cells, and spleen. It is predominantly expressed by cells of the epithelial lineage. GOLM1 is expressed at a low level in the normal liver. Expression significantly increases in virus (HBV, HCV) infected liver. Expression of GOLM1 does not increase in liver disease due to non-viral causes (alcohol-induced liver disease, autoimmune hepatitis). Increased expression in hepatocytes appears to be a general feature of advanced liver disease. In liver tissue from patients with adult giant-cell hepatitis (GCH), GOLM1 is strongly expressed in hepatocyte-derived syncytial giant cells. GOLM1 is constitutively expressed by biliary epithelial cells but not by hepatocytes.
|
|||||
TMPY-04567 | SRPK1 Protein, Human, Recombinant (His & GST) | Human | Baculovirus Insect Cells | ||
Serine / threonine-protein kinase SRPK1, also known as SFRS protein kinase 1, Serine/arginine-rich protein-specific kinase 1, SR-protein-specific kinase 1 and SRPK1, is a cytoplasm and nucleus protein that belongs to the protein kinase superfamily and CMGC Ser/Thr protein kinase family. Isoform 2 of SRPK1 is predominantly expressed in the testis but is also present at lower levels in heart, ovary, small intestine, liver, kidney, pancreas and skeletal muscle. Isoform 1 of SRPK1 is only seen in the testis, at lower levels than isoform 2. SRPK1 hyperphosphorylates RS domain-containing proteins such as SFRS1, SFRS2 and ZRSR2 on serine residues during metaphase but at lower levels during interphase. SRPK1 plays a central role in the regulatory network for splicing, controlling the intranuclear distribution of splicing factors in interphase cells and the reorganization of nuclear speckles during mitosis. SRPK1 locks onto SFRS1 to form a stable complex and processively phosphorylates the RS domain. SRPK1 appears to mediate HBV core protein phosphorylation which is a prerequisite for pregenomic RNA encapsidation into viral capsids.
|